Abstract
Background: The sentinel node (SN) concept assumes that early lymphatic metastases, if present, always are found first in the SN. The aim of this study was to determine the reliability ofthis procedure by establishing the success rate and number of failed procedures during a follow-up period of at least 2 years.
Methods: From August 1993 to November 1996, 204 consecutive patients with stage I and II cutaneous melanoma underwent SN biopsy by a triple technique. Preoperatively, all patients underwent (dynamic) lymphoscintigraphy. A gamma probe and blue dye helped localize the SN(s) during surgery, and these nodes subsequently were excised. These lymph nodes were step-sectioned and examined by routine and immunohistochemical staining. If the SN contained tumor cells, a lymphadenectomy was performed at a later date.
Results: The median follow-up time was 42 months. The success rate was 99%. Three patients developed a recurrence in the negative SN basin during follow-up, without simultaneous appearance of (locoregional) metastases.
Conclusions: With a 99% success rate and a 1.5% rate of failed SN procedures (7% falsenegative rate) after a median follow-up of 3.5 years, we concluded that the combined triple technique approach of detecting the SN was a reliable method to accurately identify and retrieve the SN.
Similar content being viewed by others
References
Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–9.
Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759–67.
Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255– 60.
Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793– 6.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.
Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976–83.
The 1st International Congress on the Sentinel Node in Diagnosis and Treatment of Cancer. Amsterdam, The Netherlands, April 7–10, 1999. Proceedings and abstracts. Eur J Nucl Med 1999; 26(Suppl):S1–S103.
Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253– 60.
Van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994;81:1769 –70.
Van Diest PJ, Peterse HL, Borgstein PJ, Hoekstra O, Meijer CJ. Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999;26(Suppl):S43–S49.
Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: longterm results of the multi-institutional randomized surgical trial. Ann Surg Oncol 1996;3:446 –52.
Stehlin JSJ, Smith JLJ, Jing BS, Sherrin D. Melanomas of the extremities complicated by in-transit metastases. Surg Gynecol Obstet 1966;122:3–14.
Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999;6:315–21.
Statius Muller MG, van Leeuwen PA, Borgstein PJ, Pijpers R, Meijer S. The sentinel node procedure in cutaneous melanoma: an overview of 6 years’ experience. Eur J Nucl Med 1999;26(Suppl): S20–S25.
Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radiolympho- scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217–24.
Glass LF, Messina JL, Cruse W, et al. The use of intraoperative radiolymphoscintigraphy for sentinel node biopsy in patients with malignant melanoma. Dermatol Surg 1996;22:715–20.
Kapteijn BA, Nieweg OE, Liem I, et al. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997;4:156–60.
Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997;132:666 –72.
Pijpers R, Borgstein PJ, Meijer S, Hoekstra OS, van Hattum LH, Teule GJ. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 1997;21:788 –92.
Bennett LR, Lago G. Cutaneous lymphoscintigraphy in malignant melanoma. Semin Nucl Med 1983;13:61–9.
Pijpers R, Collet GJ, Meijer S, Hoekstra OS. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 1995;22:1238–41.
Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993;34:1435– 40.
Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262–7.
Pijpers R, Borgstein PJ, Meijer S, et al. Transport and retention of colloidal tracers in regional lymphoscintigraphy in melanoma: influence on lymphatic mapping and sentinel node biopsy. Melanoma Res 1998;8:413– 8.
Alazraki N. Lymphoscintigraphy and the intraoperative gamma probe. J Nucl Med 1995;36:1780 –3.
Kelley MC, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol 1998; 14:283–90.
Blaheta HJ, Schittek B, Breuninger H, et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcriptionpolymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999;23:822– 8.
Van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A, et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759–64.
Borgstein P, Meijer S. Historical perspective of lymphatic tumour spread and the emergence of the sentinel node concept. Eur J Surg Oncol 1998;24:85–9.
Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998;186:275– 83.
Foster RS Jr., The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin North America 1996; 5:79 –104.
Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198: 65–9.
Ames FC, Sugarbaker EV, Ballantyne AJ. Analysis of survival and disease control in stage I melanoma of the head and neck. Am J Surg 1976;132:484 –91.
McNeer G, Cantin J. Local failure in the treatment of melanoma. The Janeway lecture, 1966. Am J Roentgenol Radium Ther Nucl Med 1967;99:791– 808.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muller, M.G.S., Borgstein, P.J., Pijpers, R. et al. Reliability of the Sentinel Node Procedure in Melanoma Patients: Analysis of Failures After Long-Term Follow-Up. Ann Surg Oncol 7, 461–468 (2000). https://doi.org/10.1007/s10434-000-0461-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0461-7